151 related articles for article (PubMed ID: 37777743)
1. Timing of SGLT2i initiation after acute myocardial infarction.
von Lewinski D; Kolesnik E; Aziz F; Benedikt M; Tripolt NJ; Wallner M; Pferschy PN; von Lewinski F; Schwegel N; Holman RR; Oulhaj A; Moertl D; Siller-Matula J; Sourij H
Cardiovasc Diabetol; 2023 Sep; 22(1):269. PubMed ID: 37777743
[TBL] [Abstract][Full Text] [Related]
2. Effect of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level and structural changes following myocardial infarction: A systematic review and meta-analysis.
Banjar S; Alharbi S; Omer I; Al Zaid N; Alghamdi A; Abuthiyab N; Alzahrani A
Int J Cardiol; 2024 Sep; 410():132239. PubMed ID: 38852858
[TBL] [Abstract][Full Text] [Related]
3. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Tripolt NJ; Kolesnik E; Pferschy PN; Verheyen N; Ablasser K; Sailer S; Alber H; Berger R; Kaulfersch C; Leitner K; Lichtenauer M; Mader A; Moertl D; Oulhaj A; Reiter C; Rieder T; Saely CH; Siller-Matula J; Weidinger F; Zechner PM; von Lewinski D; Sourij H;
Am Heart J; 2020 Mar; 221():39-47. PubMed ID: 31901799
[TBL] [Abstract][Full Text] [Related]
4. Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: a post hoc analysis of the EMMY trial.
Aziz F; Tripolt NJ; Pferschy PN; Scharnagl H; Abdellatif M; Oulhaj A; Benedikt M; Kolesnik E; von Lewinski D; Sourij H
Cardiovasc Diabetol; 2024 Apr; 23(1):145. PubMed ID: 38678253
[TBL] [Abstract][Full Text] [Related]
5. EMMY: The continued expansion of clinical applications of SGLT2 inhibitors.
Kotit S
Glob Cardiol Sci Pract; 2023 Jan; 2023(1):e202305. PubMed ID: 36890845
[No Abstract] [Full Text] [Related]
6. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
7. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin in acute myocardial infarction: the EMMY trial.
von Lewinski D; Kolesnik E; Tripolt NJ; Pferschy PN; Benedikt M; Wallner M; Alber H; Berger R; Lichtenauer M; Saely CH; Moertl D; Auersperg P; Reiter C; Rieder T; Siller-Matula JM; Gager GM; Hasun M; Weidinger F; Pieber TR; Zechner PM; Herrmann M; Zirlik A; Holman RR; Oulhaj A; Sourij H
Eur Heart J; 2022 Nov; 43(41):4421-4432. PubMed ID: 36036746
[TBL] [Abstract][Full Text] [Related]
9. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
[TBL] [Abstract][Full Text] [Related]
10. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus.
Lyu YS; Oh S; Kim JH; Kim SY; Jeong MH
Cardiovasc Diabetol; 2023 Jul; 22(1):185. PubMed ID: 37481509
[TBL] [Abstract][Full Text] [Related]
11. Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial.
Benedikt M; Mangge H; Aziz F; Curcic P; Pailer S; Herrmann M; Kolesnik E; Tripolt NJ; Pferschy PN; Wallner M; Zirlik A; Sourij H; von Lewinski D
Cardiovasc Diabetol; 2023 Jul; 22(1):166. PubMed ID: 37407956
[TBL] [Abstract][Full Text] [Related]
12. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation.
Kwon O; Myong JP; Lee Y; Choi YJ; Yi JE; Seo SM; Jang SW; Kim PJ; Lee JM
J Am Heart Assoc; 2023 Jul; 12(14):e027824. PubMed ID: 37421263
[TBL] [Abstract][Full Text] [Related]
14. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-group, controlled trial.
Khiali S; Taban-Sadeghi M; Sarbakhsh P; Khezerlouy-Aghdam N; Namdar H; Salehi R; Rezagholizadeh A; Entezari-Maleki T
Trials; 2023 Oct; 24(1):645. PubMed ID: 37803449
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC
Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127
[TBL] [Abstract][Full Text] [Related]
17. Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial.
Aziz F; Tripolt NJ; Pferschy PN; Kolesnik E; Mangge H; Curcic P; Hermann M; Meinitzer A; von Lewinski D; Sourij H;
Cardiovasc Diabetol; 2023 Jul; 22(1):184. PubMed ID: 37475009
[TBL] [Abstract][Full Text] [Related]
18. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
20. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
